€8.6M raised to fund programs in hypertension and heart failure
The French biopharmaceutical company developing cutting-edge drugs in the field of cardiovascular diseases successfully closed a €8.6M private placement and follow-on offering from European and American investors. With the reinforcement of their cash position, the company should have a 2-year financial visibility, and will be able to further advance its research programs. Quantum Genomics is developing centrally active first-in-class drugs, the Brain aminopeptidases Inhibitors (BAPAIs), with promising potential for cardiovascular diseases, especially resistant hypertension and congestive heart failure. The year 2016 will be decisive for the company which expects major milestones, including preliminary Phase IIa results with QGC001 in hypertension (Q3-2016), and the initiation of a Phase IIa study with QGC101 in heart failure (H2-2016).Taking into account the newly issued shares and increased cash position, we adjusted our target price on Quantum Genomics to € 14.61/share.
Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.